CN1589145A - αv整联蛋白受体拮抗剂 - Google Patents

αv整联蛋白受体拮抗剂 Download PDF

Info

Publication number
CN1589145A
CN1589145A CNA00811157XA CN00811157A CN1589145A CN 1589145 A CN1589145 A CN 1589145A CN A00811157X A CNA00811157X A CN A00811157XA CN 00811157 A CN00811157 A CN 00811157A CN 1589145 A CN1589145 A CN 1589145A
Authority
CN
China
Prior art keywords
tetrahydro
oxo
nonanoic acid
pyrimidin
naphthyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA00811157XA
Other languages
English (en)
Chinese (zh)
Inventor
P·J·科莱曼
M·E·杜甘
W·哈尔岑科
G·D·哈特曼
J·H·胡钦森
R·S·梅斯纳
M·A·帕塔尼
J·J·珀金斯
王家炳
M·J·布雷斯林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1589145A publication Critical patent/CN1589145A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA00811157XA 1999-06-02 2000-05-30 αv整联蛋白受体拮抗剂 Pending CN1589145A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13710199P 1999-06-02 1999-06-02
US60/137,101 1999-06-02
US17921600P 2000-01-31 2000-01-31
US60/179,216 2000-01-31

Publications (1)

Publication Number Publication Date
CN1589145A true CN1589145A (zh) 2005-03-02

Family

ID=26834930

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA00811157XA Pending CN1589145A (zh) 1999-06-02 2000-05-30 αv整联蛋白受体拮抗剂

Country Status (28)

Country Link
US (1) US6410526B1 (enExample)
EP (1) EP1187592B1 (enExample)
JP (3) JP3808707B2 (enExample)
KR (1) KR20020021380A (enExample)
CN (1) CN1589145A (enExample)
AT (1) ATE368462T1 (enExample)
AU (1) AU749351B2 (enExample)
BG (1) BG106232A (enExample)
BR (1) BR0011108A (enExample)
CA (1) CA2373937A1 (enExample)
CY (1) CY1107746T1 (enExample)
CZ (1) CZ20014308A3 (enExample)
DE (1) DE60035779T2 (enExample)
DK (1) DK1187592T3 (enExample)
DZ (1) DZ3263A1 (enExample)
EA (1) EA200101272A1 (enExample)
EE (1) EE200100642A (enExample)
ES (1) ES2288861T3 (enExample)
HR (1) HRP20010895A2 (enExample)
HU (1) HUP0302468A2 (enExample)
IL (1) IL146378A0 (enExample)
IS (1) IS6157A (enExample)
NO (1) NO323906B1 (enExample)
PL (1) PL353364A1 (enExample)
PT (1) PT1187592E (enExample)
SK (1) SK17442001A3 (enExample)
TR (1) TR200103431T2 (enExample)
WO (1) WO2000072801A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246889A (zh) * 2013-02-07 2016-01-13 赛弗卢尔生命科学公司 氟化整联蛋白拮抗剂
US9593114B2 (en) 2013-02-07 2017-03-14 Scifluor Life Sciences, Inc. Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
CN107531699A (zh) * 2015-02-19 2018-01-02 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
CN109476632A (zh) * 2016-07-05 2019-03-15 洛克菲勒大学 四氢萘啶戊酰胺整联蛋白拮抗剂
CN110167933A (zh) * 2016-11-08 2019-08-23 百时美施贵宝公司 作为αV整联蛋白抑制剂的唑酰胺和胺
CN110167934A (zh) * 2016-11-08 2019-08-23 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
JP2003520271A (ja) 2000-01-24 2003-07-02 メルク エンド カムパニー インコーポレーテッド αｖインテグリン受容体拮抗薬
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
AU7793501A (en) * 2000-07-26 2002-02-05 Merck & Co Inc Alpha v integrin receptor antagonists
AU2001290772A1 (en) * 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
AU2001296439A1 (en) * 2000-10-04 2002-04-15 Merck & Co., Inc. Phosphoric acid salt of an integrin receptor antagonist
AU2002246757B2 (en) * 2001-01-03 2006-02-02 Merck & Co., Inc. Methods and compositions for treating periodontal disease
CN1247258C (zh) 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
BR0316876A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos de tiazol e composição farmacêutica compreendendo o mesmo
US7288655B2 (en) * 2003-03-07 2007-10-30 Merck & Co., Inc. α v integrin receptor antagonists
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
EA017864B1 (ru) 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
AU2010252280A1 (en) 2009-05-25 2012-01-19 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
DK3929196T3 (da) 2013-09-24 2023-09-25 Fujifilm Corp Farmaceutisk sammensætning af en nitrogenholdig forbindelse eller salt deraf, eller metalkompleks deraf
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
US10118929B2 (en) 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202615058A (zh) 2024-06-12 2026-04-16 美商艾拉倫製藥股份有限公司 失養強直性肌肉蛋白質激酶（ｄｍｐｋ）ｉｒｎａ組成物及其使用方法
WO2025259743A1 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dual conjugate compounds for extrahepatic delivery

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843798A (en) 1973-03-12 1974-10-22 Stanley Drug Products Inc Methods and compositions for inducing resistance to bacterial infections
US5025025A (en) 1989-06-28 1991-06-18 Ciba-Geigy Corporation (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity
FI934894L (fi) 1991-05-07 1993-11-05 Merck & Co Inc Fibrinogenreceptorantagonister
JPH07503944A (ja) 1991-11-22 1995-04-27 イエダ　リサーチ　アンド　デベロツプメント　カンパニー　リミテツド Ａｒｇ−ｇｌｙ−ａｓｐ配列の非ペプチド代替物およびそれらからなる医薬組成物
EP0667773A4 (en) 1992-10-14 1996-09-25 Merck & Co Inc FIBRINOGEN RECEPTOR ANTAGONISTS.
ATE227567T1 (de) 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
EP0880511A4 (en) 1996-01-16 1999-06-16 Merck & Co Inc Integrin receptor antagonists
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
ES2185009T3 (es) 1996-04-10 2003-04-16 Merck & Co Inc Antagonistas de alfa y beta 3'.
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
JP2002511052A (ja) 1996-08-29 2002-04-09 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
CA2268940A1 (en) * 1996-10-30 1998-05-07 Merck & Co., Inc. Integrin antagonists
JP2001504456A (ja) 1996-10-30 2001-04-03 メルク エンド カンパニー インコーポレーテッド インテグリン拮抗薬
CA2277273C (en) 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
SK9192000A3 (en) * 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
ES2243016T3 (es) 1997-12-17 2005-11-16 MERCK & CO., INC. Antagonistas de receptores de integrinas.
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
DE69830806T2 (de) 1997-12-17 2006-04-27 Merck & Co., Inc. Integrinrezeptor antagonisten
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246889B (zh) * 2013-02-07 2018-07-31 赛弗卢尔生命科学公司 氟化整联蛋白拮抗剂
CN105246889A (zh) * 2013-02-07 2016-01-13 赛弗卢尔生命科学公司 氟化整联蛋白拮抗剂
US9593114B2 (en) 2013-02-07 2017-03-14 Scifluor Life Sciences, Inc. Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
US9717729B2 (en) 2013-02-07 2017-08-01 Scifluor Life Sciences, Inc. Fluorinated integrin antagonists
US9802933B2 (en) 2013-02-07 2017-10-31 Scifluor Life Sciences, Inc. Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
US11685737B2 (en) 2013-02-07 2023-06-27 Ocuterra Therapeutics, Inc. Fluorinated integrin antagonists
US9518053B2 (en) 2013-02-07 2016-12-13 Scifluor Life Sciences, Inc. Fluorinated integrin antagonists
US10106537B2 (en) 2013-02-07 2018-10-23 Scifluor Life Sciences, Inc. Fluorinated integrin antagonists
CN108690022B (zh) * 2013-02-07 2021-08-17 赛弗卢尔生命科学公司 氟化整联蛋白拮抗剂
US10155758B2 (en) 2013-02-07 2018-12-18 Scifluor Life Sciences, Inc. Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
CN108690022A (zh) * 2013-02-07 2018-10-23 赛弗卢尔生命科学公司 氟化整联蛋白拮抗剂
US12497399B2 (en) 2013-02-07 2025-12-16 Ocuterra Therapeutics, Inc. Fluorinated integrin antagonists
US12286432B2 (en) 2015-02-19 2025-04-29 Ocuterra Therapeutics, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
US11685738B2 (en) 2015-02-19 2023-06-27 Ocuterra Therapeutics, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
CN107531699A (zh) * 2015-02-19 2018-01-02 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
CN109476632A (zh) * 2016-07-05 2019-03-15 洛克菲勒大学 四氢萘啶戊酰胺整联蛋白拮抗剂
CN110167933B (zh) * 2016-11-08 2022-06-21 百时美施贵宝公司 作为αV整联蛋白抑制剂的唑酰胺和胺
CN110167934B (zh) * 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
CN110167934A (zh) * 2016-11-08 2019-08-23 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
CN110167933A (zh) * 2016-11-08 2019-08-23 百时美施贵宝公司 作为αV整联蛋白抑制剂的唑酰胺和胺

Also Published As

Publication number Publication date
EE200100642A (et) 2003-02-17
IS6157A (is) 2001-11-13
JP2006206604A (ja) 2006-08-10
ES2288861T3 (es) 2008-02-01
CY1107746T1 (el) 2013-04-18
SK17442001A3 (sk) 2002-03-05
EP1187592A2 (en) 2002-03-20
BG106232A (en) 2002-06-28
NO323906B1 (no) 2007-07-16
HRP20010895A2 (en) 2003-08-31
BR0011108A (pt) 2002-03-19
AU5724600A (en) 2000-12-18
US6410526B1 (en) 2002-06-25
IL146378A0 (en) 2002-07-25
WO2000072801A3 (en) 2007-10-11
CA2373937A1 (en) 2000-12-07
JP3808707B2 (ja) 2006-08-16
HUP0302468A2 (hu) 2003-11-28
CZ20014308A3 (cs) 2002-03-13
DE60035779T2 (de) 2008-04-30
PT1187592E (pt) 2007-10-19
ATE368462T1 (de) 2007-08-15
WO2000072801A2 (en) 2000-12-07
EP1187592A4 (en) 2002-11-06
DE60035779D1 (de) 2007-09-13
DZ3263A1 (fr) 2000-12-07
NO20015858L (no) 2002-02-04
DK1187592T3 (da) 2007-11-05
JP2004500326A (ja) 2004-01-08
AU749351B2 (en) 2002-06-27
EP1187592B1 (en) 2007-08-01
JP2006232844A (ja) 2006-09-07
KR20020021380A (ko) 2002-03-20
PL353364A1 (en) 2003-11-17
NO20015858D0 (no) 2001-11-30
TR200103431T2 (tr) 2002-06-21
EA200101272A1 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
JP3808707B2 (ja) αｖインテグリン受容体拮抗薬
US7153862B2 (en) αv integrin receptor antagonists
CN1114403C (zh) 玻连蛋白受体拮抗剂
CN1197860C (zh) 抗原结合片段i抑制剂
CN1280291C (zh) 用作磷酸二酯酶抑制剂的取代的吡咯并吡啶酮衍生物
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
JP4787447B2 (ja) αｖインテグリン受容体拮抗薬
CN1284944A (zh) 整联蛋白受体拮抗剂
CN1468241A (zh) 作为gabaa受体配体的杂环化合物
CN1209060A (zh) 玻连蛋白受体拮抗剂
CN1694708A (zh) TGFβ的抑制剂
CN1304406A (zh) 作为玻连蛋白拮抗剂的杂环甘氨酰β－丙氨酸衍生物
CN1802375A (zh) 用于治疗炎性疾病的β－咔啉
CN1976931A (zh) 用以治疗炎症的β－咔啉
CN1856305A (zh) 吡啶衍生物及其作为尾加压素ⅱ拮抗剂的应用
CN1236767C (zh) 玻璃体结合蛋白受体拮抗剂
CN1464878A (zh) 用作hiv逆转录酶抑制剂的三环2－吡啶酮化合物
CN1284955A (zh) 整联蛋白受体拮抗剂
CN1738817A (zh) 玻璃体结合蛋白受体的新的拮抗剂衍生物,它们的制备方法,它们作为药物的应用和包含它们的药物组合物
CN1322133A (zh) 玻璃体结合蛋白受体拮抗剂
CN1471512A (zh) 偕取代的αvβ3整联蛋白拮抗剂
HK1034960A (en) Integrin receptor antagonists
HK1035182A (en) Integrin receptor antagonists
HK1100491A (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
HK1096961A (en) Pyrido(2,3-d)pyrimidine-2,4-diamines as pde 2 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication